Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Other 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

Paclitaxel 164Fulvestrant 158Trastuzumab 157pembrolizumab 146Letrozole 136Carboplatin 120pertuzumab 105Capecitabine 105Cyclophosphamide 103Specimen Handling 101Anastrozole 91palbociclib 86abemaciclib 83Magnetic Resonance Spectroscopy 80exemestane 77Docetaxel 76ribociclib 74Tamoxifen 74trastuzumab deruxtecan 67Radiotherapy 62Biopsy 58Surveys and Questionnaires 55olaparib 53Gemcitabine 53130-nm albumin-bound paclitaxel 53sacituzumab govitecan 51Blood Specimen Collection 50Taxes 49Standard of Care 49eribulin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Bupropion × Breast × 1 year × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡